A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is
The recent advancement in the field of biomedical technologies has opened up new possibilities in the treatment of autoimmune disorders such as multiple sclerosis (MS). Here, we report the production of soluble complexes between the myelin oligodendrocytic glycoprotein (MOG) 79-90 peptide and a genetically engineered murine MHC class II molecule A q . Using mouse model of MS, we demonstrate that the generated complexes are functional and able to ameliorate the clinical signs and reduce thedoi:10.1080/13102818.2010.10817822 fatcat:h4ft2lyl7vehleepv5bcwvd4de